When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option
GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophyla
The European Commission has become the first regulator worldwide to approved a therapy from Gilead Sciences for people with multidrug-resistant (MDR) HIV infection that only needs to be tak
In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning demand for its shingles vaccine Shin